CCL17 and neoplasm: As for the neutrophil and FOXP3-positive cell, previous studies have reported that tumor-associated neutrophil can recruit FOXP3-positive cells through chemokine ligand 2 (CCL)–chemokine receptor-2 (CCR) and CCL17–CCR4 pathways to form immunosuppressive TIME and promote tumor progression (36).